Furthermore, the potential therapeutic biomarkers, CD244, S100 calcium-binding protein P (S100P), and vascular endothelial growth factor C (VEGFC), were identified by random forest approach (RFA), which were validated in LN mice. This evidence concerns the gene CD244 and lobular neoplasia.